NEUROCRINE BIOSCIENCES INC Operating Lease, Right-of-Use Asset, Amortization Expense
NEUROCRINE BIOSCIENCES INC (NBIX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $3.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $900.00K, a 87.32% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $2.70M, a 62.50% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $6.60M, a 2100.00% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $7.10M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month |
|---|---|---|---|
| 2026-06-30 | $900.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $3.60M 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $2.70M 10-Q · filed 2026-05-05 | ||
| 2025-09-30 | $6.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $13.70M derived: sum of 2 quarters · filed 2026-07-31 | $20.90M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $7.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $14.30M 10-Q · filed 2026-07-31 | |
| 2025-03-31 | $7.20M 10-Q · filed 2026-05-05 | ||
| 2024-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $3.90M 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $3.60M 10-Q · filed 2025-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |